The TRT injection guide.
How testosterone injections work: esters and their pharmacokinetics, the evidence behind intramuscular vs subcutaneous routes, injection site anatomy, technique, and what gets monitored. This covers the science and technique; dosing and protocol decisions belong with your prescriber.
Reviewed June 1, 2026
- Different esters (cypionate, enanthate, undecanoate) release testosterone at different rates, and that is what drives injection frequency, not arbitrary convention.
- Subcutaneous injection of testosterone is now well-evidenced and often preferred for more stable levels; ventrogluteal is the recommended IM site.
- Hematocrit is the primary safety lab on TRT. Testosterone stimulates red blood cell production, and a rising hematocrit increases clot risk.
- The 2023 TRAVERSE trial (n=5,246) found testosterone non-inferior to placebo for major cardiovascular events in high-risk men.
Understanding testosterone esters.
Injectable testosterone is dispensed as an ester: a chemical modification at the testosterone molecule's 17β-hydroxyl group that makes it oil-soluble and slows its release after injection. The ester is cleaved by tissue enzymes, releasing free testosterone into circulation. The length of the ester chain determines how long that release takes, which is why different esters have very different injection frequencies. The ester itself is inactive; only free testosterone produced after cleavage is biologically active.
- 01Testosterone propionate (3-carbon ester): half-life approximately 2–3 days. Very short, requires frequent injections. Historically used in bodybuilding; associated with more post-injection pain (PIP) due to the short ester's chemistry. Rarely used in modern TRT.
- 02Testosterone enanthate (7-carbon ester): half-life approximately 7 days. Injected once or twice weekly in most TRT protocols. Commonly suspended in sesame oil (Delatestryl). Peak levels at approximately 24–72 hours post-injection; trough just before the next injection.
- 03Testosterone cypionate (8-carbon ester): half-life approximately 8 days, functionally very similar to enanthate and used interchangeably clinically. FDA-standard formulation (Depo-Testosterone) uses cottonseed oil. Takes approximately 4–5 weeks to reach steady-state serum levels.
- 04Testosterone undecanoate (11-carbon ester): half-life 20–34 days depending on the oil carrier. Injected every 10–14 weeks. In the US, administered by a healthcare provider under a REMS (Risk Evaluation and Mitigation Strategy) program due to the rare risk of pulmonary oil microembolism (POME). Not typically self-injected.
Intramuscular vs subcutaneous: what the evidence shows.
The intramuscular route has been the traditional standard since the 1950s. Subcutaneous injection of testosterone became common in clinical practice in the 2010s, driven by studies showing comparable efficacy with better tolerability, more stable serum levels, and patient preference for the smaller needle.
- 01Pharmacokinetics. IM produces a higher and faster peak (Cmax typically at 24–48 hours) and a deeper trough, creating more fluctuation. SC produces a slower, lower peak and a more stable trough-to-peak ratio. Al-Futaisi et al. (2006) and Spratt et al. (2017 JCEM) both demonstrated SC testosterone achieves therapeutic serum levels with comparable outcomes.
- 02Needle gauge and length. IM requires a 22–25G, 1–1.5 inch needle to reach muscle. SC requires a 25–29G, 0.5-inch needle, similar to an insulin needle. Many patients find SC significantly more comfortable.
- 03Volume limits. SC generally accommodates up to 0.5–1 mL per site comfortably; IM can accommodate up to 2–3 mL in large muscles. Very high-concentration formulations may require IM for volume reasons.
- 04Both are clinically valid. Neither route is superior in all situations. Route selection should be made with a prescriber based on formulation, frequency, and individual factors.
Injection site anatomy.
For IM injection, site selection determines both efficacy and safety. The four common sites carry different risk profiles. The ventrogluteal site (gluteus medius/minimus, accessed from the lateral hip) has become the recommended primary IM site in nursing and clinical practice guidelines. It is free from major nerves and blood vessels, has a consistent depth, and avoids the sciatic nerve entirely.
- 01Ventrogluteal (recommended primary IM site). Over gluteus medius/minimus, lateral hip. No sciatic nerve risk. Consistent muscle depth. Recommended by StatPearls and current nursing literature for IM injection.
- 02Vastus lateralis (outer thigh). Large surface area, easy to visualise for self-injection. Mid-third of the outer thigh. Low nerve and vascular risk. Good for self-administered injection.
- 03Deltoid. Convenient for clinical settings; volume limited to ~1 mL. Injection point is between the acromion and the armpit. Risk of radial nerve damage if the site is too low or lateral.
- 04Dorsogluteal (upper outer buttock): falling out of favour. Once standard; now discouraged in current clinical guidance due to proximity to the sciatic nerve (the largest nerve in the body). Documented cases of sciatic nerve injury from dorsogluteal injection exist in the literature. StatPearls lists this site as higher-risk and no longer the preferred choice.
Injection technique: what the evidence supports.
- 01Z-track technique. Pull the skin 2–3 cm laterally before inserting the needle, then inject, wait 10 seconds, withdraw, release the skin. This seals the injection tract and prevents oil from tracking back into subcutaneous tissue. Reduces post-injection leakage and local reactions. PLOS ONE meta-analysis (2021) confirmed Z-track reduces injection site reactions.
- 02Aspiration: no longer routinely recommended. WHO and CDC guidelines no longer recommend aspirating (pulling back the plunger before injecting) for IM vaccinations, and many clinicians have extended this to testosterone. The recommended IM sites do not overlie major blood vessels; the risk of intravascular injection with proper site selection is extremely low. Some practitioners still teach aspiration for dorsogluteal specifically, given its proximity to the superior gluteal vessels.
- 03Air-lock technique. Drawing 0.1–0.2 mL of air after the medication into the syringe. The air follows the medication into the muscle, pushing the last of the oil out of the needle track. Evidence is mixed on whether this meaningfully reduces PIP or leakage but is a low-risk technique commonly taught.
- 04Needle gauge and oil temperature. Thicker oil formulations are harder to inject through a narrow needle. Using a 21G draw needle and switching to a 23–25G injection needle balances draw speed and injection comfort. Warming the oil to body temperature (holding the syringe in the hand or armpit for 30–60 seconds) reduces viscosity and makes injection easier.
Post-injection pain (PIP) is common, especially with propionate and shorter esters, high-concentration formulations, and cold oil. It typically peaks 12–24 hours post-injection and resolves within 2–3 days. Prevention: proper site selection, body-temperature oil, slow injection rate (no faster than 1 mL per 30 seconds), Z-track, and site rotation.
Hematocrit and erythrocytosis.
Testosterone stimulates erythropoiesis (the production of red blood cells) through two converging mechanisms: (1) stimulating erythropoietin (EPO) production in the kidneys, which drives RBC production; and (2) suppressing hepcidin, the master regulator of iron availability, making more iron available for haemoglobin synthesis. The result is elevated haemoglobin and hematocrit: the percentage of blood volume occupied by red blood cells. This is the most common adverse finding on TRT monitoring.
- 01Incidence. Approximately 10–25% of men on TRT develop elevated hematocrit (>50–52%). Mild elevation is often asymptomatic. Severe elevation increases blood viscosity and thrombosis risk.
- 02Endocrine Society 2018 threshold. Withhold or dose-reduce testosterone if hematocrit exceeds 54%. This is a clinical guideline threshold, not an absolute pathology cutoff. Any rising hematocrit warrants discussion with a prescriber.
- 03Monitoring schedule. CBC at baseline before starting, again at 3 months, 6 months, then annually if stable. More frequent if hematocrit was elevated on prior check or dose was changed.
- 04Management. First-line is dose reduction or frequency increase (more frequent smaller doses = lower peak testosterone = less erythrocytosis). Phlebotomy (blood donation or therapeutic phlebotomy) is commonly used but the evidence supporting its long-term safety and efficacy in this context was described as limited in a 2024 systematic review.
Estradiol and aromatase inhibitors.
Testosterone converts to estradiol via the aromatase enzyme (CYP19A1), concentrated primarily in adipose tissue. Higher body fat means more aromatisation. Men on TRT will have some estradiol elevation as a result, and how much varies by individual, body composition, dose, and injection frequency.
- 01Routine estradiol monitoring is not recommended by the 2018 Endocrine Society guideline in asymptomatic men on TRT. Check only if symptoms develop.
- 02Routine AI use is not guideline-supported. Aromatase inhibitors (anastrozole, letrozole) reduce estradiol but suppress its beneficial effects on bone density, cardiovascular health, and potentially cognition. There are no RCTs establishing efficacy or safety for AI use in TRT.
- 03Symptomatic high estradiol includes gynecomastia, water retention, and in some men mood changes or sexual dysfunction. Symptomatic low estradiol includes joint pain, low bone density, depression, and erectile dysfunction. These risks from excessive AI use are real.
- 04Approaches before AI. Increasing injection frequency (more frequent, smaller injections = lower Cmax = less aromatisation), reducing dose, and reducing body fat are first-line adjustments per guideline logic.
Cardiovascular safety: what TRAVERSE found.
The TRAVERSE trial (2023) is the first large pre-specified randomised cardiovascular outcomes trial for testosterone. It enrolled 5,246 men aged 45–80 with hypogonadism and either pre-existing cardiovascular disease or multiple risk factors (the exact population where CV risk is highest). Primary endpoint: time to first MACE (heart attack, stroke, or CV death).
- 01Primary endpoint: non-inferior. TRT was not inferior to placebo for MACE. No statistically significant increase in heart attack or stroke was seen.
- 02Prostate: no increase in cancer. Rates of prostate cancer were similar between groups. Rates of acute urinary retention and prostate surgery were also similar.
- 03Atrial fibrillation: slightly elevated. A higher rate of AF was seen in the testosterone arm (3.5% vs 2.4%), a pre-specified secondary endpoint. Whether this is causal is debated.
- 04Important context. TRAVERSE enrolled high-risk men. Extrapolation to all TRT users, including younger, healthier men, requires caution in both directions.
Fertility considerations.
Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. The hypothalamus detects circulating testosterone and reduces GnRH output; this drops LH and FSH from the pituitary. Without LH, the testes stop producing intratesticular testosterone. Without FSH, Sertoli cells cannot support spermatogenesis. Azoospermia (zero sperm count) is common within 3–6 months of starting TRT and sperm quality begins declining within 2–4 weeks.
- 01HCG co-administration. Human chorionic gonadotropin mimics LH and can maintain intratesticular testosterone during TRT. Studies show HCG 500 IU every other day preserves semen parameters in most men even during gonadotropin suppression from TRT.
- 02Recovery after stopping. For TRT use under 1 year: 90% of men return to baseline sperm concentration within 12 months of stopping; 100% by 24 months per a pooled analysis. Longer use may require pharmacological assistance (HCG or clomiphene) for non-spontaneous recovery.
- 03Alternatives for symptomatic hypogonadism in men wanting fertility. Clomiphene and enclomiphene (selective oestrogen receptor modulators) raise endogenous testosterone by blocking hypothalamic negative feedback without suppressing HPG. These are off-label for hypogonadism but widely used for fertility-preserving management.
Women and testosterone therapy.
Testosterone is not only relevant to men. A 2019 Global Consensus Position Statement, endorsed by 11 international medical societies including the Endocrine Society, the International Menopause Society, and the International Society for Sexual Medicine, found Level 1, Grade A evidence (the strongest possible) that systemic testosterone therapy significantly increases satisfying sexual events, desire, arousal, and orgasmic function in postmenopausal women with hypoactive sexual desire disorder (HSDD). No female-specific testosterone product is currently approved by the FDA; male formulations are used off-label at approximately 1/10th the male dose.
FAQ.
Subcutaneous or intramuscular for testosterone?
Both are evidence-supported. SC produces more stable serum levels with smaller, more comfortable needles. IM is the traditional route and accommodates larger volumes. Which is appropriate depends on the formulation, concentration, and your prescriber's recommendation, not a guide default.
What is the difference between testosterone cypionate and enanthate?
Functionally very similar: both are long-acting esters with half-lives of 7–8 days, injected once or twice weekly, and used interchangeably in most clinical contexts. Cypionate is the FDA-standard US formulation (Depo-Testosterone in cottonseed oil); enanthate is historically in sesame oil. Some people report tolerating one carrier better than the other.
Why rotate injection sites?
Repeating the same site causes local irritation, scar tissue (fibrosis), and eventually impaired absorption as fibrotic tissue is less vascular. Rotating spreads this out. PepCue logs which site you used last to make rotation easy.
What is hematocrit and why does it matter on TRT?
Hematocrit is the percentage of your blood volume made up of red blood cells. Testosterone stimulates red blood cell production via erythropoietin and hepcidin suppression. A high hematocrit thickens the blood and increases thrombosis risk. The Endocrine Society guideline recommends dose adjustment or pause if hematocrit exceeds 54%. This is why CBC is a required monitoring lab.
Should I take an aromatase inhibitor on TRT?
The 2018 Endocrine Society guideline does not recommend routine AI use during TRT. There are no RCTs establishing efficacy or long-term safety of AIs in this context, and low estradiol in men carries its own risks (bone loss, mood changes, erectile dysfunction). The guideline position is: treat symptoms, not lab numbers. Any change to a protocol is for your prescriber.
Will TRT affect my heart?
The TRAVERSE trial (2023, n=5,246) found testosterone non-inferior to placebo for major adverse cardiovascular events (heart attack, stroke, CV death) in men with established CV disease or multiple risk factors. Atrial fibrillation was slightly more common in the TRT arm. This is the best available evidence: a pre-specified randomised outcomes trial, not observational data.
Does TRT cause prostate cancer?
TRAVERSE found no increase in prostate cancer rates on TRT vs placebo. Long-term meta-analyses of TRT studies have not confirmed a causal link. PSA is still monitored on TRT because testosterone can cause early PSA elevation (a known effect in the first 6–12 months), but PSA rise ≠ cancer, and the monitoring is precautionary. Active prostate cancer is a contraindication to TRT.
Will TRT make me infertile?
TRT reliably suppresses spermatogenesis. Most men on TRT will have significantly reduced or zero sperm counts within 3–6 months. This is reversible for most men (90% recover baseline sperm counts within 12 months of stopping, 100% by 24 months per pooled data). HCG co-administration can preserve spermatogenesis during TRT. All reproductive-age men should discuss fertility before starting.
Can women use testosterone?
Yes. The 2019 Global Consensus Position Statement (11 international societies) found strong evidence (Level 1, Grade A) for testosterone therapy in postmenopausal women with hypoactive sexual desire disorder (HSDD). No FDA-approved female product exists; male formulations are used off-label at much lower doses. Monitoring for virilisation is standard.
What blood tests do I need on TRT?
Baseline before starting, then at 3 months, 6 months, then annually: total testosterone (trough timing), CBC with hematocrit, PSA (men over 40), lipid panel, and estradiol if symptomatic. Free testosterone, SHBG, and metabolic panel are common additions. See the bloodwork guide for what each marker means.
Sources.
- [1]Bhasin S et al.: Testosterone Therapy in Men With Hypogonadism: Endocrine Society Clinical Practice Guideline · J Clin Endocrinol Metab, 2018
- [2]Lincoff AM et al.: Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE) · N Engl J Med, 2023
- [3]Spratt DK et al.: Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection · J Clin Endocrinol Metab, 2017
- [4]Al-Futaisi AM et al.: Subcutaneous administration of testosterone: a pilot study · Saudi Med J, 2006
- [5]Davis SR et al.: Global Consensus Position Statement on the Use of Testosterone Therapy for Women · J Clin Endocrinol Metab, 2019
- [6]Testosterone cypionate (Depo-Testosterone): FDA prescribing information · U.S. FDA / DailyMed
- [7]Testosterone undecanoate (Aveed): FDA REMS prescribing information · U.S. FDA / DailyMed
- [8]Samplaski MK & Nangia AK: Testosterone as a contraceptive: what men should know · World J Mens Health, 2019
- [9]Testosterone-induced erythrocytosis: mechanisms and phlebotomy evidence review · Blood Advances, 2025
- [10]StatPearls: Intramuscular injection technique · NCBI Bookshelf / StatPearls
- [11]Z-track and intramuscular injection technique: meta-analysis · PLOS ONE, 2021
- [12]Sperm recovery after testosterone therapy: pooled analysis · PubMed / NCBI
Cite this page
PepCue. “The TRT injection guide.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/guides/trt-injection.
Track your protocol in PepCue.
Log doses, run the calculators, follow the evidence, and keep peptides, GLP-1s, TRT and labs in one private timeline.